Voyager gets $165M up front from Neurocrine for gene therapies

Voyager Therapeutics Inc. (NASDAQ:VYGR) will receive $165 million up front from Neurocrine Biosciences Inc. (NASDAQ:NBIX) in exchange for a license to four of Voyager's neurology gene therapy programs. Voyager is eligible for $1.7 billion in milestones across the four programs.

Neurocrine gains rights to develop and commercialize VY-AADC, which is in the Phase II RESTORE-1 trial to treat Parkinson's disease; VY-FXN01, which is in preclinical testing to treat Friedreich ataxia; plus two programs yet to be determined...